About Scioderm
Scioderm is a Healthcare company based in Durham (United States) founded in 2012, and was acquired by Amicus Therapeutics in August 2015. Topical therapies are developed for chronic skin diseases treatment. Scioderm has raised $37 million across 3 funding rounds from investors including Amicus Therapeutics, Redmile Group and Morgenthaler. The company has 6 employees. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is Scioderm, Inc. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
Scioderm was founded in 2012 in Durham, United States, within the biotechnology sector. Topical products are developed to meet needs in treating chronic skin diseases. The lead product, SD-101, is advanced for managing skin manifestations of Epidermolysis Bullosa, a rare genetic connective tissue disorder appearing in early life. Operations focus on dermatological innovations for such conditions.
- Headquarters Durham, United States
- Employees 6
- Stage Acquired
- SectorsHealthcare
- Website sderm.com
- Social LinkedIn X
- Acquired by Amicus Therapeutics (Aug 2015)
- Legal Name Scioderm, Inc
- Total Equity Funding$37M (USD)
in 3 rounds
- Latest Funding Round$20M (USD), Series B
Dec 2014
- InvestorsAmicus Therapeutics
& 3 more
- Employee Count6
- Acquired byAmicus Therapeutics
(Aug 2015)
Funding Insights of Scioderm
Scioderm has successfully raised a total of $37M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37M
- Total Rounds 3
- Last Round Series B — $20M
- First Round $1M
(Mar 2013)
- Investors Count 3
All 3 funding rounds of Scioderm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $20M | Series B | – | – | |
| Apr 2013 | $16M | Series A | – | – | |
| Mar 2013 | $1M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Scioderm
Scioderm has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Amicus Therapeutics, Redmile Group and Morgenthaler.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity investment firm | morgenthaler.com | Portola Valley, United States | ||
Investments are made in US life sciences and energy companies. | technologypartners.com | Palo Alto, United States | ||
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Developer of therapies for rare and orphan diseases | 2002 | amicusrx.com | Philadelphia, United States |
Investor details for Scioderm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Scioderm
4 dated milestones of Scioderm across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Scioderm is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $20.0M.
- Exit Acquired by Amicus Therapeutics.
Competitors of Scioderm
Scioderm has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of Scioderm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Scioderm (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Scioderm
Scioderm was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Scioderm is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Scioderm is a funded company, having raised a total of $37M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Mar 2013.
Scioderm has 6 employees.
Scioderm was founded in 2012 in Durham, United States, within the biotechnology sector. Topical products are developed to meet needs in treating chronic skin diseases. The lead product, SD-101, is advanced for managing skin manifestations of Epidermolysis Bullosa, a rare genetic connective tissue disorder appearing in early life. Operations focus on dermatological innovations for such conditions.
Scioderm's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
Scioderm has 4 investors. Key investors include Amicus Therapeutics, Redmile Group, Morgenthaler, and Technology Partners.
Scioderm operates through Scioderm, Inc.
Yes. Scioderm was acquired by Amicus Therapeutics in August 2015.